Meclizine Hydrochloride Tablets distributed nationwide by Amerisource Health Services LLC are being recalled. The two affected NDCs are 60687-775-65 and 60687-775-11. The recall is due to failed tablet specifications. Stop using the product and contact a healthcare provider for guidance immediately.
Failed tablet specifications.
Consumers and healthcare providers should stop using this product immediately. Contact Amerisource Health Services LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Meclizine is used to prevent and treat nausea, vomiting, and motion sickness. The 12.5 mg tablet is a common dose for adults for short-term relief.
A failure to meet tablet specifications can lead to incorrect dosage, which may affect safety and efficacy.
This recall is not described as part of a broader industry pattern in the provided data.
Consumers with the affected lots may face dosing uncertainty. The recall is active and distributed nationwide.
FDA enforcement page and recall notice linked to the NDCs and lot numbers.
Recall notice indicates a letter will be issued with next steps. Specific refund timelines are not provided.
Keep the recall letter, packaging, and any correspondence with the pharmacy or provider. Photograph the product and packaging for records.
NDC 60687-775-65: 50 Tablets per carton [5 x 10], Rx Only, 697 cartons distributed nationwide in the U.S. NDC 60687-775-11: 12.5 mg Individual Dose, Rx Only, 697 cartons distributed nationwide. Distributor: Amerisource Health Services LLC, Columbus, OH 43217. Recall date: 2026-03-16. Status: Active. Manufactured by Meclizine Hydrochloride supplier. The package form includes both multi-dose cartons and single-dose units.
No injuries or incidents have been reported.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
KVK-Tech Inc. recalled 31,676 packages of Oxycodone Hydrochloride Tablets on January 14, 2026. Defective seals may cause tablets to fall out, posing a health risk. Customers should stop using the product immediately and seek guidance from healthcare providers.
27,868 blister packs of Sucralfate Tablets, 1 g, distributed nationwide by American Health Packaging are recalled. The recall stems from CGMP deviations that prevent the firm from assuring product identity, strength, quality and purity. Health providers and consumers should stop using the product immediately and await guidance.
FDA recalls Carbamazepine Extended-Release Tablets, 400 mg, distributed nationwide by American Health Packaging. The recall cites failed dissolution specifications and class II classification. Consumers should stop using and contact healthcare providers for guidance.
Chlorpromazine Hydrochloride tablets distributed nationwide by American Health Packaging are recalled after a polyester coil used in packaging showed presence of a micro-organism in a specific lot. No tablets were contaminated. Consumers and healthcare providers should stop using this product immediately and contact Amerisource Health Services LLC for guidance.
A high-severity recall covers chlorpromazine hydrochloride tablets distributed nationwide by American Health Packaging. A foreign substance linked to a polyester coil packaging component was detected at the manufacturing site. No tablets were contaminated. Stop using the product and contact the distributor for guidance.
American Health Packaging recalled 873 cartons of Chlorpromazine Hydrochloride Tablets, USP, 200 mg, after foreign substances were detected in product packaging. A specific lot of auxiliary polyester coil contained a micro-organism, posing a high health risk. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
A recall of chlorpromazine hydrochloride tablets is active nationwide in the United States. A specific lot of packaging material to coils used in manufacturing contained a foreign substance with a microorganism detected. Tablets themselves tested negative for microorganisms. Consumers and healthcare providers should stop using the product immediately and contact Amerisource Health Services LLC or
A recall is active for Sucralfate Tablets, USP 1 gram distributed by American Health Packaging. The firm filed for Chapter 11 in September 2024, triggering CGMP deviations and questions about product identity, strength, quality and purity. The recall affects 26,992 blister packs distributed nationwide. Stop using the product and contact Amerisource Health Services or your clinician for guidance.